Pramiracetam

DB13247ApprovedSmall molecule

Pramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. It was also previously approved in the United States with orphan drug... Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression.

Chemical structure of Pramiracetam
Formula / weight
C14H27N3O2 · 269.389 g/mol (avg)

Resolves to

Compound
UNII4449F8I3LECAS68497-62-1ChEMBLCHEMBL159776ChEBI135110
Clinical / RWD
ATCN06BX16
Structure
InChIKeyZULJGOSFKWFVRX-UHFFFAOYSA-NSMILESCC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C
Targets
P08912CHRM5

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
9Marketed productsAcross 1 country and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 3 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Pramiracetam, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In